Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).

Pardo-Lozano R, Farré M, Yubero-Lahoz S, O'Mathúna B, Torrens M, Mustata C, Pérez-Mañá C, Langohr K, Cuyàs E, Carbó Ml, de la Torre R.

PLoS One. 2012;7(10):e47599. doi: 10.1371/journal.pone.0047599. Epub 2012 Oct 24.

2.

Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion.

Perfetti X, O'Mathúna B, Pizarro N, Cuyàs E, Khymenets O, Almeida B, Pellegrini M, Pichini S, Lau SS, Monks TJ, Farré M, Pascual JA, Joglar J, de la Torre R.

Drug Metab Dispos. 2009 Jul;37(7):1448-55. doi: 10.1124/dmd.108.026393. Epub 2009 Apr 6.

3.

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.

O'Mathúna B, Farré M, Rostami-Hodjegan A, Yang J, Cuyàs E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, de la Torre R.

J Clin Psychopharmacol. 2008 Oct;28(5):523-9. doi: 10.1097/JCP.0b013e318184ff6e.

PMID:
18794647
4.

Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.

Farré M, Abanades S, Roset PN, Peiró AM, Torrens M, O'Mathúna B, Segura M, de la Torre R.

J Pharmacol Exp Ther. 2007 Dec;323(3):954-62. Epub 2007 Sep 21.

PMID:
17890444

Supplemental Content

Loading ...
Support Center